Loading...
•
Jun 30, 2022
Adaptimmune Q2 2022 Earnings Report
Adaptimmune's financial results for the second quarter of 2022 were reported, with revenue of $5.5 million and a net loss of $44.5 million.
Key Takeaways
Adaptimmune reported financial results for the second quarter ended June 30, 2022. Revenue was $5.5 million, Total Operating Expenses were $49.3 million, and Net Loss was $44.5 million.
BLA submission for afami-cel on track for Q4 2022
Overall response rate was 36% in heavily pre-treated patients across both types of sarcomas
Adaptimmune has implemented rigorous cost containment measures
Company funded into early 2024
Adaptimmune
Adaptimmune
Forward Guidance
The Company believes that its existing cash, cash equivalents and marketable securities, together with the additional payments under the Strategic Collaboration and License Agreement with Genentech, will fund the Company’s current operations into early 2024